Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.

[1]  L. Gladieff,et al.  CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer , 2022, International Journal of Gynecological Cancer.

[2]  Timothy D. Solberg,et al.  An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication , 2021, Nature Cancer.

[3]  E. Kohn,et al.  Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline , 2021, JCO global oncology.

[4]  D. Tu,et al.  Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[5]  D. Matei,et al.  Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  D. Chi,et al.  Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study , 2020, International Journal of Gynecological Cancer.

[7]  G. Scambia,et al.  Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850) , 2020, International Journal of Gynecological Cancer.

[8]  E. Kohn,et al.  PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Reuss,et al.  Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – final analysis of AGO DESKTOP III/ENGOT- ov20 , 2020, Geburtshilfe und Frauenheilkunde.

[10]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[11]  I. Licaj,et al.  [Retrospective study: Late surgery post chemotherapy versus after 3-4 cures in treatment of advanced ovarian cancer]. , 2019, Bulletin du cancer.

[12]  Danielle M. Enserro,et al.  Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. , 2019, The New England journal of medicine.

[13]  Selen Bozkurt,et al.  Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. , 2019, JCO clinical cancer informatics.

[14]  I. Ray-Coquard,et al.  Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials) , 2019, Annals of Oncology.

[15]  D. Timmerman,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Ishikawa,et al.  Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy? , 2019, Journal of gynecologic oncology.

[17]  S. Mathoulin-Pélissier,et al.  The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME) , 2019, BMJ Open.

[18]  S. Kehoe,et al.  Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  B. Rosen,et al.  Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study. , 2017, Gynecologic oncology.

[20]  G. Bogani,et al.  The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC–IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study , 2017, International Journal of Gynecologic Cancer.

[21]  R. Burger,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Xiaoxiang Chen,et al.  The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc–IV high-grade serous ovarian cancer , 2017, Archives of Gynecology and Obstetrics.

[23]  C. Mathelin,et al.  Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer? , 2016, Oncology.

[24]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[25]  P. Colombo,et al.  Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. , 2014, Gynecologic oncology.

[26]  M. Del Pilar Estevez Diz,et al.  Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. , 2014, Gynecologic oncology.

[27]  F. Guyon,et al.  Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery , 2014, Annals of Surgical Oncology.

[28]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[29]  Jason D. Wright,et al.  Defining the limits of radical cytoreductive surgery for ovarian cancer. , 2011, Gynecologic oncology.

[30]  F. Guyon,et al.  Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined? , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[31]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[32]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[33]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[34]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[35]  D. Chi,et al.  Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. , 2006, Gynecologic oncology.

[36]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[37]  A. Sato,et al.  Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. , 2008, Japanese journal of clinical oncology.